News | Radiation Therapy | March 25, 2021

Northern Sydney Cancer Centre Partners with Sun Nuclear as Newest SunCHECK Platform Reference Site

Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK Quality Management Platform.

March 25, 2021 — Sun Nuclear Corporation announced that Australia's Northern Sydney Cancer Centre (NSCC) is now a reference site for the SunCHECK Quality Management Platform. The center joins leading clinics worldwide already in the reference site program. Globally, SunCHECK technology is used by more than 1,000 users in nearly 60 countries – for integrated, automated and independent quality assurance in radiation therapy.

In partnering with Sun Nuclear, the NSCC will support development of best practices for clinical use, advise on ongoing platform development, and serve as a regional resource for a rapidly-growing community of SunCHECK users. The NSCC is an integrated cancer care network, provided by the Northern Sydney Local Health District (NSLHD). As a public facility with university affiliations, the NSCC is actively involved in cancer research and dedicated to improving outcomes for patients and their families. The center treats more than 1,400 patients annually, using three Varian Medical Systems® linear accelerators and a robust auto-planning program. The NSCC also uses an Elekta brachytherapy system.

Jeremy Booth, Head of Medical Physics for the NSCC, stated that the center is a pioneer in advanced treatments, initiating its IMRT program in 2001 and its SBRT program in 2007. Today, the NSCC remains focused on continually investigating the feasibility of technological changes, including motion management.   

"As a busy clinic with an active research program, we need an efficient, proven quality assurance mechanism," said Booth. "SunCHECK provides the comprehensive functionality and departmental integration we were looking for and offers the efficiency our workload demands."  

The SunCHECK Platform automates and integrates quality management, enabling radiation therapy departments to standardize patient and machine quality assurance (QA) workflows among staff, machines, and locations. A secure, browser-based network architecture connects multiple systems and can support different geographic locations, offering a top-down view through a single dashboard, supported by a single database.

SunCHECK Patient software incorporates Plan Checks, Secondary Calculations, Pre-Treatment QA and In-Vivo Monitoring all in a single workflow. SunCHECK™ Machine software integrates all Machine QA needs, including daily, monthly, and annual QA; automated imaging, MLC and VMAT QA; and data trending. Plus, device integration with the Daily QA 3, IC PROFILER and ArcCHECK arrays enables further automation and centralization of data.

Additional SunCHECK Platform reference sites include: St. George's Cancer Care Centre (Christchurch, New Zealand), Sterling Hospitals Group (Ahmadabad, India), Iridium Kankernetwerk (Antwerp, Belgium), Sant Pau (Barcelona, Spain), ONCORAD (Toulouse, France), The Clatterbridge Cancer Centre (Liverpool, UK), I.R.C.C.S di Candiolo (Candiolo, Italy), UF Health Cancer Center at Orlando Health (Florida, U.S.), and Mosaic Life Care (Missouri, U.S.).

For more information: www.sunnuclear.com

Related Content

The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS' 
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of
Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

Cancer tissue being bombarded by targeted alpha particles. The generator developed by Los Alamos National Laboratory holds uranium-230, which decays to thorium-226. Further decay produces short-lived daughter isotopes, emitting four more alpha particles resulting in a very high combined radiation dose to destroy cancer cells.

News | Radiation Therapy | March 23, 2021
March 23, 2021 — Improved options for cancer treatment...